Alzinova AB (publ) (ALZ.ST)
Alzinova AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Mölndal, VG, SE. The stock last traded at $0.42, up 1.33% on the session, giving a market capitalisation of $43.3M. Its beta of 1.08 implies it has historically moved more than the broad market.
Alzinova AB (publ) is a Swedish biotechnology company dedicated to advancing novel immunotherapies against Alzheimer's disease. Their primary investigational product, ALZ-101, is a vaccine specifically designed to target oligomers responsible for Alzheimer's. Additionally, they are developing ALZ-201, a monoclonal antibody aimed at neutralizing harmful amyloid-beta (Aß) oligomers. Established in 2011, the company's operations are headquartered in Mölndal, Sweden.
Alzinova AB (publ) is most often compared with the following Healthcare names: